Paul E. Sax

The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States

Milton C Weinstein, A David Paltiel, Anne M Neilan, 2017, The Journal of infectious diseases.

Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy.

B. Walker, M. Hirsch, J. Martinez-Picado, 1999, The Journal of infectious diseases.

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.

P. Sax, L. Taylor, B. Schwartzapfel, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The long‐term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model‐based approach

K. Freedberg, Y. Yazdanpanah, E. Losina, 2007, HIV medicine.

Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease

M. Weinstein, R. Walensky, K. Freedberg, 2005, Journal of acquired immune deficiency syndromes.

The clinical role and cost-effectiveness of long-acting antiretroviral therapy.

M. Weinstein, R. Walensky, K. Freedberg, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil

R. Walensky, K. Freedberg, P. Sax, 2015, Journal of acquired immune deficiency syndromes.

Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US

Milton C Weinstein, Taige Hou, A David Paltiel, 2015, HIV clinical trials.

Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

M. Weinstein, R. Walensky, K. Freedberg, 2013, Annals of Internal Medicine.